Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.
NCT00184626 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 97
Last updated 2017-02-24
Summary
This trial is conducted in Asia. The aim of the trial is to compare the glycaemic control of Insulin glargine versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in combination with metformin in subjects with Type 2 Diabetes.
Conditions
- Diabetes
- Diabetes Mellitus, Type 2
Interventions
- DRUG
-
biphasic insulin aspart
- DRUG
-
insulin glargine
- DRUG
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 35 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-09-10
- Primary Completion
- 2005-10-24
- Completion
- 2005-10-24
Countries
- Turkey (Türkiye)
Study Locations
More Related Trials
-
Observational Study on Safety and Efficacy of Biphasic Insulin Aspart in Type 2 Diabetes Patients
NCT00834262 ·Status: COMPLETED
-
Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes
NCT00282451 ·Status: COMPLETED ·Phase: PHASE4
-
Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin
NCT02582242 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes
NCT01467323 ·Status: COMPLETED ·Phase: PHASE3
-
Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 Diabetes
NCT01526980 ·Status: COMPLETED ·Phase: PHASE2
-
A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification
NCT02906917 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Two Biphasic Insulin Aspart 30 Treatment Regimens in Subjects With Type 2 Diabetes Not Achieving HbA1c Treatment Targets on OADs Alone
NCT01215435 ·Status: COMPLETED ·Phase: PHASE4
-
Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy
NCT00598793 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes
NCT00184613 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens
NCT01365507 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes Mellitus When Failing on OADs
NCT00537277 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Biphasic Insulin Aspart 30 With Metformin in Type 2 Diabetes
NCT00624364 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)
NCT01212913 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Biphasic Insulin Aspart 30 on Blood Glucose Control in Subjects With Type 2 Diabetes
NCT00280046 ·Status: COMPLETED ·Phase: PHASE3
-
Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes
NCT01697631 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus.
NCT00476437 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes
NCT01865305 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes
NCT00184600 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes
NCT01009580 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Two Formulations of Biphasic Insulin Aspart 70
NCT01523041 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes
NCT01520818 ·Status: COMPLETED ·Phase: PHASE3
-
Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019)
NCT00393705 ·Status: COMPLETED ·Phase: PHASE4
-
Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes
NCT00600626 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 Diabetes
NCT01536028 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes
NCT02500706 ·Status: COMPLETED ·Phase: PHASE3